Alana Harris Dent

Array ( [id] => 18243654 [patent_doc_number] => 20230075965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => USES OF BIOMARKERS FOR IMPROVING IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/793581 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 151026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -114 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18243654 [patent_doc_number] => 20230075965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => USES OF BIOMARKERS FOR IMPROVING IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/793581 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 151026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -114 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17260041 [patent_doc_number] => 20210373026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => METHODS FOR THE DETECTION AND QUANTIFICATION OF CIRCULATING TUMOR CELL MIMICS [patent_app_type] => utility [patent_app_number] => 17/142662 [patent_app_country] => US [patent_app_date] => 2021-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17142662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948138 [patent_doc_number] => 20210206829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => TREATMENT OF CD47+ DISEASE CELLS WITH SIRP ALPHA-FC FUSIONS [patent_app_type] => utility [patent_app_number] => 17/133489 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17133489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168880 [patent_doc_number] => 20230035491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => METHODS, KITS AND COMPOSITIONS FOR REDUCING CARDIOTOXICITY ASSOCIATED WITH CANCER THERAPIES [patent_app_type] => utility [patent_app_number] => 17/785385 [patent_app_country] => US [patent_app_date] => 2020-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17785385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18197879 [patent_doc_number] => 20230051398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => MATERIALS AND METHODS FOR EXTRACELLULAR VESICLE DETECTION [patent_app_type] => utility [patent_app_number] => 17/784170 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808357 [patent_doc_number] => 20210130910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => METHODS AND ASSAYS RELATING TO CIRCULATING TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 17/101028 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808638 [patent_doc_number] => 20230382972 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-11-30 [patent_title] => CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS [patent_app_type] => utility [patent_app_number] => 17/773800 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883807 [patent_doc_number] => 20210170002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => SLC45A2 PEPTIDES FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/092043 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17092043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808638 [patent_doc_number] => 20230382972 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-11-30 [patent_title] => CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS [patent_app_type] => utility [patent_app_number] => 17/773800 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837688 [patent_doc_number] => 20210145700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/079326 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17079326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555800 [patent_doc_number] => 20210000948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => PD-1 Peptide Inhibitors [patent_app_type] => utility [patent_app_number] => 17/026447 [patent_app_country] => US [patent_app_date] => 2020-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17026447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17983857 [patent_doc_number] => 20220349893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => METHODS FOR THE TREATMENT OF ARID1A-DEFICIENT CANCERS [patent_app_type] => utility [patent_app_number] => 17/642512 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16597 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16523799 [patent_doc_number] => 20200397879 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => METHOD OF TREATING WITH A PEPTIDE [patent_app_type] => utility [patent_app_number] => 17/017358 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16525264 [patent_doc_number] => 20200399344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-24 [patent_title] => NK CELL-DIRECTED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 17/017117 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57940 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539390 [patent_doc_number] => 20200405803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => PD-1 Peptide Inhibitors [patent_app_type] => utility [patent_app_number] => 17/015658 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015658 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945828 [patent_doc_number] => 20220332845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => INHIBITION OF MTHFD1L FOR USE IN HYPERTROPHIC HEART DISEASE AND HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/639950 [patent_app_country] => US [patent_app_date] => 2020-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17991291 [patent_doc_number] => 20220357328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => SUPERIOR BIOMARKER SIGNATURE TO PREDICT THE RESPONSE OF A BREAST CANCER PATIENT TO CHEMOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/641064 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19827201 [patent_doc_number] => 12247973 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-11 [patent_title] => Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/003750 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 10698 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850445 [patent_doc_number] => 20220280486 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => COMBINED CANCER THERAPY INVOLVING CHEMICAL ACTIVATION OF INTEGRINS AND TARGETED CELL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/632183 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632183 [rel_patent_id] =>[rel_patent_doc_number] =>)